Electrophysiology

The cardiac subspecialty of electrophysiology (EP) diagnoses and treats arrhythmias. This includes use of pacemakers to treat bradycardia, implantable cardioverter defibrillators (ICD) for tachycardia, heart failure and patients at risk of sudden cardiac arrest, and cardiac ablation treatments to treat heart rhythm disorders.

Johnson & Johnson MedTech launches new 2D ICE catheter
The company says the new device was designed to improve image quality, provide additional maneuverability and simplify ablation workflows for electrophysiologists.
Johnson & Johnson MedTech ordered to pay $147M for antitrust violations
The company told Cardiovascular Business it respectfully disagrees with the jury's decision and is evaluating all possible legal options going forward. The Association of Medical Device Reprocessors, meanwhile, celebrated the news.
Cardiologists are first in world to use new cooling device to terminate AFib during surgery
Patients often develop AFib during cardiac surgery, leading to longer hospital stays, additional healthcare costs and a higher risk of mortality. Cooling the oblique sinus of the patient's heart as soon as AFib starts to develop may represent a new way to stop the problem in its tracks.
World’s first leadless LBBAP procedures linked to ‘promising’ outcomes
Cardiologists are turning to leadless pacemakers more and more for cardiac pacing, but those devices have not previously been able to perform LBBAP. This new analysis includes new data on the world’s very first leadless LBBAP procedures.
AI predicts LBBB risk in TAVR patients prior to treatment
The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

Newsweek ranked the 50 best heart hospitals in the world

10 ways to improve care for in-hospital cardiac arrest

“Nearly 300,000 cardiac arrests occur in hospitals in the United States each year, and only about 25% of people survive to hospital discharge after these types of events,” according to one author of a new analysis published in Circulation: Cardiovascular Quality and Outcomes.

QDOT MICRO Biosense Webster Johnson and Johnson

Next-gen RF catheter from Biosense Webster improves QOL in patients with paroxysmal AFib

After 12 months, researchers found that the device was associated with control of AFib in 99% of patients and relief from AFib symptoms in 93.1% of patients.

Samir Kapadia, MD, Cleveland Clinic, explains the WATCH TAVR study results that combined LAAO with transcatheter aortic valve replacement at TCT 2023. #TCT2023 #TAVR #Watchman #LAAO

TAVR and LAAO at the same time? Samir Kapadia breaks down the WATCH-TAVR trial

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview.

PARTNER 3, Evolut and more: TAVR takes the spotlight in 4 late-breaking clinical trials at TCT 2023

All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology.

Medtronic extravascular ICD Aurora EV-ICD MRI SureScan

FDA approves Medtronic’s extravascular ICD for abnormal heart rhythms

The Aurora EV-ICD MRI SureScan is similar in size and shape to traditional ICDs, but it is implanted outside of the patient’s heart and veins.

Technology that creates interactive holograms of the heart cleared by FDA

SentiAR's CommandEP interface facilitates 3D models of the heart, made possible through augmented reality.

Video of Christina Albert, MD, MPH chair, Department of Cardiology, Cedars-Sinai, explaining the changing approaches to sudden cardiac arrest. #SCA #SCD #ESC #ESC23 #ESC2023

Changing approaches to the treatment of sudden cardiac arrest

Preventing sudden cardiac arrest involves managing risk factors such as hypertension, hyperlipidemia and diabetes. We spoke to Christine Albert, MD, about this and much more at ESC 2023.

Artificial intelligence (AI) is being developed to help make cardiovascular clinical trials more efficient, lead to faster advances in patient care, and bring possible new treatments to heart patients more quickly. The major cardiac research center of Icahn School of Medicine at Mount Sinai announced today that it signed a memorandum of understanding with the Chiba Institute of Technology (CIT) to collaborate on using AI to enhance cardiovascular disease research.

Mount Sinai partners with the Chiba Institute of Technology on AI to transform cardiovascular research

Agreement aims to use AI to help make cardiology clinical trials more efficient and lead to faster advances in patient care.

Electrophysiology

Johnson & Johnson MedTech launches new 2D ICE catheter

Johnson & Johnson MedTech ordered to pay $147M for antitrust violations

Cardiologists are first in world to use new cooling device to terminate AFib during surgery

World’s first leadless LBBAP procedures linked to ‘promising’ outcomes

AI predicts LBBB risk in TAVR patients prior to treatment